Clinical data demonstrate the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small ...
Sep 8, 2025
0
38
In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after ...
Jun 27, 2025
0
20
Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Jun 1, 2025
0
20
Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to ...
May 27, 2025
0
19
Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma. Among these, thymic carcinoma is the more aggressive subtype, characterized by high invasiveness, ...
Mar 12, 2025
0
12
Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using antihistamines in patients receiving second-line immunotherapy (IO) for bladder cancer may improve outcomes.
Feb 20, 2025
0
21
Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for small-cell lung cancer (SCLC), one of the most aggressive and difficult-to-treat cancers. Published this ...
Dec 18, 2024
0
29
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic ...
Oct 24, 2024
0
15
The addition of the cancer immunotherapy drug atezolizumab to the standard of care concurrent chemoradiation (cCRT) did not improve overall survival for patients with limited-stage small cell lung cancer (LS-SCLC) in the ...
Sep 30, 2024
0
27
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when ...
Sep 30, 2024
0
31
